

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

American Journal of Otolaryngology–Head and Neck Medicine and Surgery

journal homepage: www.elsevier.com/locate/amjoto



Check for updates

Dysphonia in COVID-19 patients: Direct or indirect symptom?

ARTICLE INFO

Keywords Dysphonia COVID-19 SARS-CoV-2 Voice Infection Reflux

Dear Editor,

We read the article entitled: "Prevalence of dysphonia due to COVID-19 at Salahaddin General Hospital, Tikrit City, Iraq" [1]. Authors investigated the prevalence of dysphonia in hospitalized patients with coronavirus disease 2019 (COVID-19). They observed 22.3% of dysphonic patients who reported more frequently fatigue, nasal obstruction and diarrhea. At the rigid laryngoscope, authors observed bowing of the vocal folds. They reported that dysphonia persisted at least 1-month posthospitalization. The study of dysphonia in COVID-19 patients is important regarding the neurotropism of the virus and the expression of angiotensin converting enzyme 2 (ACE2) in vocal folds [2,3]. We congratulate authors for this research. However, we wish to draw attention to many points.

First, authors did not consider laryngopharyngeal reflux disease (LPRD), which is an important confounding factor associated with dysphonia and throat symptoms [4]. The prevalence of LPR in Asia and Middle East was estimated to 10 to 30% [5] and, in a context of pandemic, the LPRD prevalence could be increased. Indeed, patients who developed COVID-19 may have an increase of their stress and anxiety, which are associated with autonomic nerve dysfunction, esophageal sphincter relaxations (sympathetic innervation of esophageal sphincters) and back flow of gastric content into the esophagus and upper aerodigestive tract [6,7]. The increase of LPRD in hospitalized COVID-19 patients has, moreover, been suspected in a recent study [8]. LPRD is usually associated with erythema and edema of the laryngopharyngeal region [4] as observed by Al-Ani et al. who identified edema and bowing of the vocal cords in dysphonic patients [1]. Authors also reported that dysphonic patients had more frequently nasal obstruction than non-dysphonic individuals. Interestingly, recent studies supported that the gaseous pharyngeal reflux events may reach nasopharynx and the back of inferior turbinate, leading to reflux-related nasal obstruction [9,10]. Second, hospitalized COVID-19 may require oral and inhaled corticosteroids regarding the dyspnea, which concerned all patients in the study of Al-Ani et Rashid [1]. The use of inhaled corticosteroids is another confounding factor that may be associated with vocal cord dryness and dysphonia [11]. Thus, the report of the proportion of patients benefiting from inhaled corticosteroids in dysphonic and non-dysphonic groups makes sense to better understand the study results.

Third, authors did not report the proportion of patients with postnasal drip and rhinorrhea. This information is however important because posterior rhinorrhea may be associated with throat sticky mucus, throat clearing, and secondary laryngitis that may be associated with dysphonia. Interestingly, the association between posterior rhinorrhea and dysphonia was reported by Azzam et al. in patients with dysphonia and COVID-19 [11].

We congratulate Al-Ani *et* Rashid for the study that reports the importance to consider dysphonia as direct or indirect symptom of COVID-19. According to our experience in Paris Hospitals, regarding the high proportion of long-term intubated patients with COVID-19 in intensive care units, we believe that future studies will probably report a higher prevalence of dysphonia in hospitalized patients who had post-intubation laryngeal damage, i.e. glottic stenosis, necrosis, glottis insufficiency or palsy.

Acknowledgments

None.

References

- Al-Ani RM, Rashid RA. Prevalence of dysphonia due to COVID-19 at Salahaddin General Hospital, Tikrit City, Iraq. Am J Otolaryngol 2021;42(5):103157. https://doi.org/10.1016/j.amjoto.2021.103157.
- [2] Lechien JR, Circiu MP, Crevier-Buchman L, Hans S. Post-COVID-19 paradoxical vocal fold movement disorder. Eur Arch Otorhinolaryngol 2021;278(3):845–6. https://doi.org/10.1007/s00405-020-06391-z.
- [3] Descamps G, Verset L, Trelcat A, Hopkins C, Lechien JR, Journe F, Saussez S. ACE2 protein landscape in the head and neck region: The conundrum of SARS-CoV-2 infection. Biology (Basel) 2020;9(8):235. https://doi.org/10.3390/biology9080235.

- [4] Lam P, Wei WI, Hui Y, Ho WK. Prevalence of pH-documented laryngopharyngeal reflux in chinese patients with clinically suspected reflux laryngitis. Am J Otolaryngol 2006;27(3):186–9. https://doi.org/10.1016/j.amjoto.2005.09.012.
- [5] Kim SI, Lechien JR, Ayad T, Jia H, Khoddami SM, Enver N, Raghunandhan SK, Hamdan AL, Eun YG. Management of laryngopharyngeal reflux in Asia. Clin Exp Otorhinolaryngol 2020;13(3):299–307. https://doi.org/10.21053/cep.2019.01669
- [6] Wang AM, Wang G, Huang N, Zheng YY, Yang F, Qiu X, Chen XM. Association between laryngopharyngeal reflux disease and autonomic nerve dysfunction. Eur Arch Otorhinolaryngol 2019;276(8):2283–7. https://doi.org/10.1007/s00405-019-05482-w.
- [7] Huang WJ, Shu CH, Chou KT, Wang YF, Hsu YB, Ho CY, Lan MY. Evaluating the autonomic nervous system in patients with laryngopharyngealreflux. Otolaryngol Head Neck Surg 2013;148(6):997–1002. https://doi.org/10.1177/ 0194599813482103.
- [8] Jiang G, Cai Y, Yi X, Li Y, Lin Y, Li Q, Xu J, Ke M, Xue K. The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: a retrospective study. J Med Virol 2020;92(10):2124–9. https:// doi.org/10.1002/imv.25998.
- [9] Hamizan AW, Choo YY, Loh PV, Abd Talib NF, Mohd Ramli MF, Zahedi FD, Husain S. The association between the reflux symptoms index and nasal symptoms among patients with non-allergic rhinitis. J Laryngol Otol 2021;v135(2):142–6. https://doi.org/10.1017/S0022215120002492.
- [10] Gray ST, Sedaghat AR. Treatment of laryngopharyngeal reflux may decrease subjective symptoms of nasal congestion and objective measures of nasal resistance.

- JAMA Otolaryngol Head Neck Surg 2017;143(5):483–4. https://doi.org/10.1001/
- [11] Azzam AAA, Samy A, Sefein I, ElRouby I. Vocal disorders in patients with COVID 19 in Egypt. Indian J Otolaryngol Head Neck Surg 2021:1–7. https://doi.org/ 10.1007/s12070-021-02663-0.
 - Jerome R. Lechien a,b,c,* , Maria R. Barillari d , Lisa G. De Marrez b , Stephane Hans
 - ^a Elsan Group, Paris, France
- ^b Department of Otorhinolaryngology-Head & Neck Surgery, Foch Hospital, Paris Saclay University, Paris, France
 - ^c Department of Otorhinolaryngology and Head and Neck Surgery, CHU Saint-Pierre, Belgium
- ^d Division of Phoniatrics and Audiology, Department of Mental and Physical Health and Preventive Medicine, L. Vanvitelli University, Naples, Italy
- * Corresponding author at: Laboratory of Anatomy and Cell Biology, Faculty of Medicine, University of Mons (UMONS), Avenue du Champ de mars, 6, B7000 Mons, Belgium.

E-mail address: Jerome.Lechien@umons.ac.be (J.R. Lechien).